Emmaus Life Sciences Q3 revenue falls after NIT licensing deal
EMMA•Emmaus Life Sciences' third-quarter revenue fell 44% year over year to $1.89 million after its U.S. licensing agreement with NIT took effect. Net loss widened to $4.74 million, while operating expenses declined to $1.89 million after the sales force transferred to NIT.
1. Quarterly results
Emmaus Life Sciences reported third-quarter revenue of $1.89 million, down 44% year over year, primarily because direct U.S. sales declined after its licensing agreement with NIT took effect. Net loss widened to $4.74 million, or $0.07 per share. Operating expenses fell to $1.89 million following the transfer of the sales force to NIT; the company also said conflict in the Middle East adversely affected regional net revenue. It provided no specific guidance for future quarters or the full year.




